

pharmaceuticals (including HIV/AIDS pharmaceuticals through the existing and separate ViiV joint venture with Pfizer), vaccines and consumer healthcare products.

6. In South Africa, the GSK Group operates a consumer healthcare business, which manufactures, develops and markets consumer preferred and expert recommended brands in the oral health, pain relief, respiratory, nutrition, gastro-intestinal and skin health categories.
7. Pfizer CH is the consumer healthcare business of Pfizer. Pfizer CH is a global over-the-counter ("OTC") healthcare business which develops, manufactures and markets non-prescription medicines, vitamins and nutritional products. Globally, Pfizer CH offers products in five major areas: (a) Pain Management; (b) Gastrointestinal Health; (c) Respiratory; (d) Dietary Supplements; and (e) Personal Care products (e.g. lip care).
8. The Commission considered the activities of the merging parties and found that they overlap in respect of the production and supply of consumer healthcare products for cold and flu treatments and pain management treatment in South Africa. The Commission assessed the following markets:
 - 8.1. National market for multi-symptom cold and flu treatments (ATC 3 class R5A / OTC 3 class 01B1);
 - 8.2. National market for nasal preparations (ATC 3 class R1A, R1B/ OTC 3 01B2);
 - 8.3. National market for multi-symptom cold and flu treatments (ATC 3 class R5A / OTC 3 class 01B1) and topical nasal preparations (R1A / OTC 3 class 01B2);
 - 8.4. National market for multi-symptom cold and flu treatments (ATC3 class R5A / OTC class 01B1) and systemic nasal preparations ((ATC3 class R1B / 01B2);
 - 8.5. National market for multi-symptom cold and flu treatments (ATC 3 R5A/OTC 3 01B1) and antitussives (ATC 3 class R5D / OTC 3 class 01A1);
 - 8.6. National market for systematic non-narcotic analgesics (ATC 3 level of N2B/ OTC 3 02A2 and 02A2); and
 - 8.7. National market for topical analgesics (ATC 3 M2A/OTC 3 02E1).